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Abstract
Recently, we have demonstrated the feasibility of using hemodynamic response imaging (HRI), a functional mag-
netic resonance imaging (MRI) method combined with hypercapnia and hyperoxia, for monitoring vascular
changes during liver pathologies without the need of contrast material. In this study, we evaluated HRI ability to
assess changes in liver tumor vasculature during tumor establishment, progression, and antiangiogenic therapy.
Colorectal adenocarcinoma cells were injected intrasplenically to model colorectal liver metastasis (CRLM) and the
Mdr2 knockout mice were used to model primary hepatic tumors. Hepatic perfusion parameters were evaluated
using the HRI protocol and were compared with contrast-enhanced (CE) MRI. The hypovascularity and the in-
creased arterial blood supply in well-defined CRLM were demonstrated by HRI. In CRLM-bearing mice, the entire
liver perfusion was attenuated as the HRI maps were significantly reduced by 35%. This study demonstrates that
the HRI method showed enhanced sensitivity for small CRLM (1-2 mm) detection compared with CE-MRI (82%
versus 38%, respectively). In addition, HRI could demonstrate the vasculature alteration during CRLM progression
(arborized vessels), which was further confirmed by histology. Moreover, HRI revealed the vascular changes in-
duced by rapamycin treatment. Finally, HRI facilitates primary hepatic tumor characterization with good correlation
to the pathologic differentiation. The HRI method is highly sensitive to subtle hemodynamic changes induced by
CRLM and, hence, can function as an imaging tool for understanding the hemodynamic changes occurring during
CRLM establishment, progression, and antiangiogenic treatment. In addition, this method facilitated the differen-
tiation between different types of hepatic lesions based on their vascular profile noninvasively.
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Introduction
Hepatic tumors represent a major burden in the medical practice, con-
sidering their high incidence, the diagnostic difficulties, and the high
rate of morbidity and mortality. Hepatocellular carcinoma (HCC) is
the fifth most common cancer worldwide and the third most common
cause of cancer-related mortality [1]. Nowadays, early stage HCC diag-
nosis is feasible in 30% to 60% of cases, thus enabling the application
of curative strategies; however, timely and accurate diagnosis is of
paramount importance [2]. The liver is also one of the most commonly
involved organs in metastatic disease [3]. Colorectal cancer is the third
most common cancer in the United States [4]. The development of
colorectal liver metastases (CRLMs) is the main cause of death in these
patients [5].
Early diagnosis is critical for successful resection and for refined treat-
ment selection criteria in both liver pathologies [6,7]. Only a minority
of CRLM patients (<20%) are amenable to resection [8–10]. Thus,
alternative treatments are under investigation. Recently, considerable
research has focused on the search for antiangiogenic therapies for
CRLM. The immunosuppressant rapamycin (RAPA) is a highly spe-
cific inhibitor of mTOR that can further inhibit tumor growth [11],
tumor progression [12], and metastasis [13] both through its antiangio-
genic activity (by impairing the production of vascular endothelial
growth factor [VEGF]) and direct inhibition of cell proliferation and
cell cycle progression [14,15]. Tumor response to therapy is usually
assessed by measurements of tumor size using morphologic imaging
techniques. Because antiangiogenic therapies may not lead to sub-
stantial tumor mass reduction, their effect is better imaged using tech-
niques designed to assess vascular function rather than the conventional
measurements of tumor size [16–18]. Dynamic contrast-enhanced
magnetic resonance imaging (CE-MRI) has been used previously to
examine the acute and chronic effects of VEGF signaling inhibitors,
both preclinically [19–21] and clinically [22,23]. However, the physi-
ologic significance of these parameters can be complex, and there is
currently no consensus as to the best parameters to be used or the most
appropriate measurement and analysis method [24,25].
It is well known that, whereas the normal liver is supplied predom-
inantly by the portal vein, in patients with overt hepatic tumor, a
higher proportion of liver blood flow is derived from the hepatic artery
[26,27]. Moreover, even small or occult lesions may lead to subtle
changes in liver blood flow [28,29]. Therefore, monitoring hemo-
dynamical changes using perfusion imaging may facilitate the charac-
terization of the vascular profile, which can lead to earlier and more
accurate detection of hepatic tumors. This strategy was recently en-
dorsed by the European [30] and American Associations for the Study
of the Liver [31].
Today, to acquire perfusion images, intravenous administration of a
contrast agent is necessary. Multiphasic CE-MRI is currently accepted
as a reliable method for detecting and characterizing liver tumors [32].
A good separation of arterial from portal venous phases requires short
acquisition time, which leads to low spatial resolution or partial volume
coverage. Recently, we demonstrated the feasibility of hemodynamic
response imaging (HRI), a functional MRI (fMRI) method combined
with hypercapnia and hyperoxia, for monitoring changes in liver perfu-
sion and hemodynamics without the need of contrast agent administra-
tion [33,34]. We established its ability to image the hemodynamic
changes occurring under different pathologic states such us liver fibro-
sis, acute bleeding, and during liver regeneration [34,35].
In the present study, we aimed to assess the use of HRI for the
detection and characterization of the early vascular and perfusion
changes occurring during CRLM establishment, for the study of the
vascular changes in CRLM during antiangiogenic therapy, and for the
assistance to characterize the vascular profile of primary hepatic tumors.
We used the CT-26 murine colon carcinoma liver metastatic mouse
model [36] and the Mdr2 knockout mice [37] as the inflammation-
induced primary liver tumor model. HRI utility for liver tumor diag-
nosis and vascular characterization was assessed in these animal
models. TheHRI results were comparedwithCE-MRI andwere further
confirmed by histology. HRI utility for antiangiogenic effect assessment
was evaluated on CRLM-bearing mice that were treated with RAPA at
a relevant dose. In this study, the HRI method showed high sensitivity
for the vascular changes occurring in liver tumors in experimental
animal models.
Materials and Methods
Animals
For the CRLMmodel, 7- to 8-week-old male CB6F1mice were used
(31 mice). For the HCC model, 12- to 18-month-oldMdr2 knockout
mice [37] were analyzed (21 lesions in 12 mice). All experiments were
performed in accordance with the guidelines and approval of the Animal
Care and Use Committee of the Hebrew University, which holds
National Institutes of Health approval (OPRR-A01-5011).
Mouse Model of CRLM
CT-26 murine colorectal adenocarcinoma cells [36] were injected
intrasplenically to anesthetized CB6F1 mice (104 cells in 300 μl per
mouse). After 5 minutes, the spleens were removed, allowing the cells
to enter the portal circulation and to initiate liver metastases. In this
model, one to five hepatic nodules per mouse were detected by MRI
13 to 17 days after cell inoculation. In this animal model, the tumors
appeared hyperintense in T2-weighted (T2W) images (Figure 1A).
The presence of CRLM lesions was further verified by repeated
MRI scans and histologic analysis. For HRI assessment, 47 lesions
(1-5 mm in diameter) were examined, and for CE-MRI assessment,
42 lesions were analyzed. For antiangiogenic treatment surveillance,
eight CRLM-bearing mice were treated with RAPA (Fermentek Ltd,
Jerusalem, Israel) at a dosage of 2 mg/kg per day intraperitoneally.
The treatment started on the day of tumor appearance as detected
by MRI.
Magnetic Resonance Imaging
MRI experiments were performed using a horizontal 4.7-T Biospec
spectrometer (Bruker Medical, Ettlingen, Germany) with a 3.5-cm
birdcage coil. Mice were anesthetized with pentobarbital (30 mg/kg,
intraperitoneally) and placed supine. Coronal and axial T1-weighted
(T1W) spin-echo images were acquired for liver segmentation purposes
(repetition time = 360milliseconds, echo time = 18milliseconds). Tumor
assessment was done using T2W fast spin-echo images (repetition time =
2000 milliseconds, echo time = 37 milliseconds, in-plane resolution =
117 μm, slice thickness = 1 mm).
Hemodynamic Response Imaging. Changes in hepatic hemody-
namics were evaluated using the HRI protocol as previously described
[33]. In brief, the images were acquired using T2*-weighted gradient
echo images (repetition time = 147 milliseconds, echo time = 10 milli-
seconds, field of view = 3 cm, in-plane resolution = 117 μm, slice thick-
ness = 1 mm, 2 averages, 37 seconds per image) combined with
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breathing of air, air-CO2 (5%CO2, 4 L/min), and carbogen (95%O2 +
5% CO2, 4 L/min) through a homemade mask.
Contrast-Enhanced MRI. To compare HRI results to a standard
method, CE-MRI was performed with T1W FLASH sequence (repeti-
tion time = 34 milliseconds, echo time = 5 milliseconds, field of view =
3 cm, in-plane resolution = 117 μm, slice thickness = 1 mm, 1 average,
80measurements), resulting in a temporal resolution of 4 seconds. After
the 10th image, gadolinium–diethylene-triaminepenta-acetate (Gd-
DTPA, Magnetol; Soreq Radiopharmaceuticals, Yavne, Israel; 0.5 M,
100 μl) was administered through the tail vein at a dose of 0.1 mmol
Gd/kg. Signal intensity–time curves and multiphasic CE images were
calculated using an in-house program written in IDL (ITT Visual In-
formation Solutions, Boulder, CO) where hepatic arterial phase begins
4 seconds after injection and the portal venous phase begins 16 seconds
after injection.
Ultrasound
Ultrasound measurements were acquired with a 14-MHz linear
transducer (15L8s) (Sequoia-512; Acuson, Mountain View, CA) on
anesthetized mice (pentobarbital 30 mg/kg, intraperitoneally). Tumor
perfusion was assessed by CE ultrasound, by intravenous injection of
150 μl of saline through the tail vein and, 5 minutes later, by intra-
venous injection of 150 μl of contrast medium bolus (15 mg/mouse,
Definity Perflutren Lipid Microsphere; Bristol-Myers Squibb Medical
Imaging, Inc, Billerica, MA). Contrast enhancement was measured
for 15 seconds at a rate of 20 frames/second. For CE ultrasound anal-
ysis, the enhancement of each region of interest (ROI) was calculated
from time series images using dedicated functional molecular image
analysis software UIA (I-Labs, Petah-Tikva, Israel).
Image Analysis and Statistics
The number of tumors per liver and their volume assessment was
performed by using Analyze 7.0 (BIR, Mayo Clinic, Rochester, MN)
from the T2W images. HRI maps were generated as reported previously
[33,34] using IDL (Interactive Data Language of ITT Visual Informa-
tion Solutions). For healthy mice, the selected liver ROIs covered the
entire liver. For CRLM-bearing mice, tumor ROI included the entire
lesion and liver ROI included representative liver tissue far away from
the detected tumors as defined on the T2W images by using the Analyze
7.0 software. Mean ΔS values were calculated from these ROI, and re-
sults are expressed as means ± SD. The difference between groups was
analyzed by one-sided exact paired Student’s t test for n > 30 data points
and with one-sided exact Wilcoxon signed-rank test for a smaller sample
size. Statistical analyses were performed with the Instat Biostatistics soft-
ware (GraphPad Software, Inc, San Diego, CA). P < .05 was considered
statistically significant.
Figure 1. CRLM vasculature profile characterization by HRI: Representatives axial T2W images (top) and ΔSO2 (hyperoxia effect—center
row) and ΔSCO2 (hypercapnia effect—bottom) maps of healthy liver (A), small CRLM acquired during early phase (B, red arrow), and
advanced multifocal CRLM (C). Bar = 1 cm. Color scales for ΔS maps are located on the right. The HRI method clearly highlighted CRLM
from healthy liver tissue. (D) Mean ΔSO2 and ΔSCO2 values ± SD of healthy livers (n = 10) versus livers of CRLM-bearing mice (n = 10)
and CRLM (n = 30). *P < .001.
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Histology and Immunostaining
Mice were killed immediately after the final MRI scan, and their
livers with the surrounding tissues were fixed in 4% formaldehyde for
a week; the entire liver was further embedded in paraffin to preserve
good correlation to MRI orientation. Finally, the livers were sliced at
1.1-mm intervals in the same axial plane as the MRI sections. The
nodules that precisely corresponded to HRI (using the transverse
T2W images as a reference) were determined. These were then cut
(5 μm) and stained with hematoxylin-eosin (H&E) or subjected to
immunohistochemistry using anti–PECAM-1 antibodies (CD31; Bio-
care Medical, Concord, CA) and antibody against α-smooth muscle
actin (α-SMA) (dilution 1:300; Sigma, St Louis, MO). Histologic ex-
amination was conducted by an expert hepatopathologist with more
than 10 years of experience in liver pathology. The number of blood
vessels was counted in 10 randomly selected high-power microscopic
fields (HPF, magnification ×400) for each tumor, and the mean value ±
SD was determined.
Results
CRLM Vasculature Profile Characterization by HRI
Initially, we assessed the ability of HRI to detect the vascular and
perfusion changes occurring in mice with well-defined CRLM. In
healthy mice, the mean liver ΔSO2 values (the change induced by
hyperoxia) were extremely positive (95% ± 18%, n = 10 livers),
whereas the mean ΔSCO2 values (the change induced by hypercap-
nia) were negative (−40% ± 4%, n = 10 livers; Figure 1, A and D), in
agreement with the results obtained previously in rats [33]. In all the
CRLM-bearing mice, the entire liver perfusion was reduced as the
HRI reactivity maps for both hyperoxia and hypercapnia were signif-
icantly attenuated (62% ± 35% and −29% ± 9%, respectively, P <
.001) compared with healthy liver mean values (n = 10 livers; Fig-
ure 1, B–D). Moreover, the ΔSO2 and ΔSCO2 mean values of well-
defined CRLM were significantly reduced (21% ± 13% and −10% ±
7%, respectively, P < .001) compared with those of the adjacent liver
(n = 30 tumors; Figure 1, B–D). These results may reflect hypovas-
cularity of the CRLM nodules, with increased arterial blood supply.
CRLM Vasculature Profile Verification
Perfusion assessment methods and immunohistochemical staining
were applied to evaluate vessel density and blood supply distribution
of CRLM in this animal model. The hypovascularity of CRLM was
clearly evident by their pale appearance compared with the reddish
color of the adjacent liver parenchyma (Figure 2A). Furthermore, blood
vessel quantization was achieved by immunohistochemical staining,
with anti–PECAM-1 antibody (CD31), which confirmed the lower
vessel density in CRLM compared with the dense vasculature of the
liver parenchyma (Figure 2, C and D). The actual blood vessel count
per HPF in healthy livers was significantly higher (35 ± 7 vessels/HPF,
n = 8 livers) compared with CRLM (8 ± 3 vessels/HPF; n = 8 tumors,
P < .0005). The increased arterial blood supply to CRLM in this model
was assessed by using CE ultrasound (n = 3mice). Themaximum signal
intensity of CRLM was lower and observed earlier than the maximum
signal intensity of liver parenchyma (Figure 2E ). Finally, by stopping
Evans Blue perfusion during the arterial phase (n = 4 mice), we ob-
served that most of the CRLM (>1 mm) turned blue, indicating their
increased arterial blood supply (Figure 2B). These results indicate that
CRLMs (>1 mm) in this animal model are indeed hypovascular and
derive their vascular supply predominantly from hepatic arteries as
suggested by HRI. These results from the animal model are in good
agreement with the clinical knowledge regarding liver metastasis vas-
cular properties in humans [26,27].
HRI and CE-MRI Comparison
TheHRI results were further compared withmultiphasic CE-MRI in
this model. For CRLM with diameters ranging between 2 and 5 mm,
the sensitivity of both imaging methods was high. However, the HRI
method enabled detection of smaller lesions (1-2 mm) compared with
the CE-MRI method. Figure 3 demonstrates an example of an image
with three small foci. According to the arterial phase image and to the
signal intensity–time course of CRLM versus liver, only one of them
(marked with red arrow; 2. 2 mm in diameter) was enhanced, whereas
the smaller lesions in this image (marked with green arrows; 1.6 mm in
diameter) were not enhanced with Gd-DTPA (Figure 3, E andG ). The
HRI results of the same slice clearly delineated all three lesions (Figure 3,
B and C ). These results were repeated in an additional seven mice in
which approximately 60% of the tumors smaller than 2 mm were not
enhanced with CE-MRI.
Figure 2. The hypovascularity and increased arterial blood supply
of CRLM. (A) A whole liver photograph demonstrating CRLM hypo-
vascularity (arrow). (B) Evan’s Blue (EB) perfusion was stopped dur-
ing the arterial phase demonstrating the increased arterial blood
supply to CRLM (arrows). Endothelial immunohistochemical stain-
ing with PECAM-1 (CD31; brown stain) of healthy liver section (C)
and CRLM section (D) confirmed the lower vessel density of CRLM
(original magnification, ×400). (E) CE ultrasound enhancement
curves from representative CRLM-bearing mouse (liver—black,
CRLM—red and aorta—green; injection time is indicated on the
graph). The time-intensity curves of each ROI were normalized by
dividing each time point by the mean of the baseline block.
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We further extended the sample size by including additional mice
that were scanned with only one of the perfusion methods (either
HRI or CE-MRI). The sensitivity results of lesion-by-lesion analysis
for both HRI and CE-MRI are given in Table 1. In this animal model,
the sensitivity for small CRLM detection (1-2 mm in diameter) of
CE-MRI (n = 21 lesions) was 38%, whereas the sensitivity of the
HRI method was higher 82% (n = 17 lesions). For larger CRLM le-
sions (between 2 and 5 mm in diameter), the sensitivity improved
considerably for both methods, whereas CE-MRI showed a sensitivity
of 81% (17/21); the HRI sensitivity was 97% (29/30).
Assessment of the Vascular Changes during Advanced
CRLM Progression
To characterize the changes in tumor perfusion during CRLM
progression, advanced CRLM (≥7 mm in diameter) were assessed by
HRI (n = 6 tumors). Along with tumor growth, the center of these
tumors appeared hyperintense in T2W images, an appearance that
could reflect development of necrosis (Figure 4A). When we analyzed
the corresponding HRImaps, ΔSO2 values were significantly positive at
the center of these tumors (37% ± 13%, P < .01) compared with the
outer CRLM region values (Figure 4, B and D), suggesting increased
vascular density and blood content. Moreover, the ΔSCO2 values be-
came significantly negative (−27% ± 6%, P < .01) compared with
the outer CRLM region values (Figure 4, C and D). In addition, the
HRI values at the center of these tumors were also significantly different
compared with those of the adjacent liver parenchyma HRI (P < .05;
Figure 4D). Indeed, H&E staining and immunohistochemical staining
with anti–PECAM-1 antibody (CD31) and α-SMA antibody revealed
highly arborized and widened matured blood vessels at the center of
Figure 3. CRLM detectability by HRI and CE-MRI: Results from a representative mouse with several small CRLM that were analyzed with
both HRI and CE-MRI. (A) Axial T2W image with three visible CRLM (marked with arrows; bar = 1 cm). The corresponding HRI maps of
the same slice (B—ΔSO2 map; C—ΔSCO2 map). Color scales for ΔS maps are located on the left. All three lesions were clearly visible
with HRI. The multiphasic CE T1W images that were obtained before (D) and 13.2 seconds (E; arterial phase) and 26.4 seconds (F; portal
phase) after Gd-DTPA injection. Only the largest CRLM (marked with red box; 2.2 mm in diameter) was enhanced during the arterial
phase, whereas the smaller lesions (marked with green boxes; 1.6 mm) were not enhanced during the arterial phase. (G) CE-MRI signal
intensity–time curves measured from the same mouse of liver parenchyma (black), the enhanced CRLM (red), and the unenhanced
CRLM (green). The injection time is indicated on the graph.
Table 1. Sensitivity Results of Lesion-by-Lesion Analysis.
CRLM Diameter (mm) No. Detected
(True Positive)
No. Missed
(False Negative)
Sensitivity (%)
(A) HRI results
1 ≤ t < 2 mm 14 3 82
2 ≤ t < 5 mm 29 1 97
(B) CE-MRI results
1 ≤ t < 2 mm 8 13 38
2 ≤ t < 5 mm 17 4 81
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these tumors, reinforcing the HRI findings regarding increased vascu-
larity at the center of these advanced tumors (Figure 4, E–G ).
Assessment of the Vascular Changes during RAPA Therapy
To assess the use of HRI for antiangiogenic treatment evaluation, we
treated CRLM-bearing mice with RAPA. CRLM growth was delayed
by 8 days in average in the RAPA-treated mice. The HRI response to
both hyperoxia and hypercapnia of CRLM in RAPA-treated mice was
significantly attenuated compared with control-treated CRLM (Fig-
ure 5, A–C ; n = 13 tumors; P < .05), whereas the liver HRI values were
similar to those measured from untreated mice. Surprisingly, at the cen-
ter of RAPA-treated CRLM, areas with positive ΔSCO2 were detected
(Figure 5B). Blood vessel quantization (by immunohistochemical stain-
ing, with anti–PECAM-1 antibody) showed reduced vessel density in
RAPA-treated CRLM (6 ± 1.3 vessels/HPF n = 9 tumors) compared
with control-treated CRLM (9 ± 1.9 vessels/HPF n = 8 tumors, P <
.005), in agreement with the HRI map attenuation. Furthermore, most
of the vessels at the center of the RAPA-treated tumors were widened
(Figure 5, G and H ), clarifying the positive ΔSCO2 values detected in
these tumors. When analyzing vessel maturation status in these
CRLMs, we noticed that most of the vessels were stained with
α-SMA both in the RAPA-treated and untreated tumors (Figure 5, F
and I ). In addition, there were areas with reduced tumor cell density
at the center of RAPA-treated CRLM (Figure 5H ).
Vascular Profile Assessment of Primary Hepatic Lesions
To evaluate the HRI utility to study the vascular profile of primary
hepatic lesions, we used Mdr2 knockout mice as the animal model
[37]. We compared the HRI findings with the routinely used T1W,
T2W, CE-MRI, and histologic evaluation (n = 21 lesions). On T2W
images, the detected lesions were either hyperintense or isointense.
Most of these lesions were also isointense on precontrast T1W images
(see examples in Figure 6A). With CE-MRI, only some of the sus-
pected lesions were enhanced either with central enhanced foci (Fig-
ure 6, B and C ) or at the periphery of the lesion (Figure 6D). The
HRI method revealed three distinct patterns of responses: 1) hetero-
geneous HRI response with regions of high response and others with
a slightly reduced response (see example in Figure 6B ), 2) elevated HRI
response covering the entire lesion (see example in Figure 6C ), and
3) significantly reduced HRI response compared with the adjacent
inflamed liver with high ΔS values at the periphery (see example
in Figure 6D). The pathologic identification, obtained from the
Figure 4. HRI analysis of advanced CRLM. (A) Axial T2W image of a mouse with advanced CRLM (encircled, 25 days after cell injection;
bar = 1 cm) and the corresponding HRI maps (B—ΔSO2 map; C—ΔSCO2 map) of the same slice. Color scales for ΔS maps are located on
the left. The center of the tumor showed atypical HRI reactivity maps. (D) (top) Mean ΔSO2 and ΔSCO2 values ± SD of healthy liver
parenchyma (black), of central regions in advanced CRLM (pink), and of the outer regions in advanced CRLM (red) (n = 6 tumors):
*P < .01 and **P < .05. (bottom) Representative HRI time courses obtained from this mouse, of liver tissue (black), from the center of
advanced CRLM (pink), and of the outer CRLM region (red). Relevant histologic slides were stained with H&E staining (E), and immuno-
histochemical staining with PECAM-1 (F; brown stain) for endothelial cells and with α-SMA (G; red stain) for smooth muscle cells revealed
highly arborized matured blood vessels (original magnification, ×200) at the center of these tumors.
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corresponding histologic sections, could distinguish between poorly
differentiated HCC (pattern I, n = 11 lesions; Figure 6B ), well-
differentiated HCC (pattern II, n = 6 lesions; Figure 6C ), and necrotic/
cystic foci (pattern III, n = 7 lesions; Figure 6D). There was a good
correlation between the HRI classification and the pathologic differenti-
ation, which may imply a beneficial usage of HRI as a complementary
method for the assessment of the vascular profile of suspected primary
hepatic lesions.
Discussion
The widespread use of modern imaging techniques increases the detec-
tion of liver tumors. Early detection of liver malignancies, new thera-
peutic options, and new monitoring methods may improve treatment
outcome. Reliable noninvasive characterization and differentiation of
these lesions are of utmost importance for clinical practice [38]. In pri-
mary and metastatic liver malignancies, there is a relative increase in
arterial blood supply to the tumor [26,27]. Perfusion imaging has been
suggested to improve the sensitivity and specificity of liver tumor diag-
nostics [27]. It is well accepted that CE imaging techniques can im-
prove the diagnosis of liver lesions larger than 1 cm [38,39] by
showing increased arterial blood supply to the tumor with venous wash-
out. Nevertheless, even the optimized imaging techniques remain rela-
tively insensitive for the detection and vascular characterization studies
of smaller nodules. In this research, we demonstrated the applicability
of HRI, an fMRI method combined with hypercapnia and hyperoxia,
for liver tumor vascular characterization. By using HRI, the hemody-
namic changes occurring during CRLM establishment were detected,
thus enabling classification of suspected foci with high sensitivity. In
addition, the HRI method demonstrated the vascular changes induced
by RAPA treatment and facilitated primary hepatic tumor characteriza-
tion with good correlation to the pathologic differentiation.
Recently, we reported the applicability of HRI for monitoring
changes in liver perfusion and hemodynamics during liver regeneration,
fibrosis, and acute bleeding in rat models, without the need of contrast
agent administration [34,35]. We demonstrated that during CO2 en-
richment, there is an increase in portal blood flow to the liver [33]. The
resultant higher deoxyhemoglobin levels produced a decrease in fMRI
signal intensity, which is illustrated by negative ΔSCO2 values. Thus,
liver ΔSCO2 values are sensitive to changes in the ratio between the por-
tal and arterial blood supplies. The signal change induced by hyperoxia
signifies vascular density and tissue perfusion [33,40].
In this study, we demonstrated that, in mice, CRLM have distinc-
tive HRI reactivity maps compared with those obtained from healthy
livers. The reduction of negative ΔSCO2 values in response to hyper-
capnia is extremely sensitive to both tumor hypovascularity and to
the increased arterial blood supply occurring during CRLM progres-
sion. The decreased ΔSO2 values in response to hyperoxia emphasize
the hypovascularity of CRLM nodules. Moreover, HRI values of
Figure 5. The vascular changes during RAPA therapy. (A and B) Representatives axial T2W images (top) and enlarged HRI maps of the
marked tumors (bottom) of control-treated mouse (A) and RAPA-treated mouse (B). Bar = 1 cm (A). Color scales for ΔS maps are located
on both sides. (C) Mean ΔSO2 and ΔSCO2 values ± SD of control-treated CRLM (red; n= 30 tumors) and RAPA-treated CRLM (green; n=
13 tumors): *P < .05. The ΔSCO2 maps of RAPA-treated tumors showed pixels with positive reactivity to hypercapnia differing from
control-treated CRLM. Relevant histologic slides were immunohistochemically stained with PECAM-1 (CD31—red stain; D, E, G, H)
for endothelial cells or with α-SMA (F, I; red stain) for smooth muscle cells (original magnification, ×200 [D, G], ×40 [E, F, H, I]). CD31
staining demonstrated widened blood vessels at the center of the RAPA-treated tumors. Anti–α-SMA staining confirmed that most of the
tumor vessels were covered with smooth muscle cells, explaining the moderate antiangiogenic effect of RAPA on these CRLMs.
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healthy livers were significantly higher compared with those from
livers of CRLM-bearing mice. This phenomenon may be explained
by the notion that, in the presence of overt CRLM, a higher pro-
portion of liver blood flow is derived from the hepatic artery, thus
changing the entire liver hemodynamic in CRLM-bearing mice
[28,41]. The CRLM mouse model used in this study revealed vascu-
lar alterations and pathologic appearance similar to those detected in
human CRLM [42]. However, the rate of tumor progression in this
model was faster than the kinetics known in CRLM patients.
In the described CRLM animal model, the sensitivity to detect
small metastases (1-2 mm) by using HRI was significantly higher
(82%) compared with multiphasic CE-MRI (38%). Previous studies
showed that small CRLM (<520 μm) are hypovascular [42], and only
advanced CRLM (>2000 μm) showed an exclusively arterial blood
supply [42,43]. This observation may explain the enhanced detect-
ability of HRI compared with multiphasic CE-MRI. Whereas multi-
phasic CE-MRI detects only the increased arterial blood supply of
CRLM, HRI could also demonstrate the reduced vessel density occur-
ring during the early phases of CRLM progression. Furthermore, the
use of contrast agents, in both CTand MRI, could be associated with
nephrotoxicity, especially in patients with risk factors such as renal
failure, vascular disease, and diabetes [44]. The HRI method may pro-
vide a safer alternative for these patients.
The high sensitivity of HRI for small CRLM and the spatial infor-
mation derived from these maps were further used to classify suspected
CRLM lesions in their early growth phase by using a machine learning
approach [45] (Figure W1). We showed that the recall (sensitivity) and
precision (equal to positive predictive value) of HRI for suspected
CRLM confirmation (≤1.6 mm) were 77% and 88%, respectively.
The ability to detect subtle hemodynamic changes during CRLM
establishment can assist to understand the metastasis development
and progression mechanism and to develop drugs directed to the early
growth phase.
Identification of new noninvasive monitoring techniques for asses-
sing early tumor response to therapy is a major need and could facilitate
decisions regarding therapy continuation or replacement. The assess-
ment of RAPA treatment effect by HRI revealed alterations in CRLM
vasculature growth pattern that were further confirmed by histologic
findings. Whereas the RAPA therapy reduced tumor vascularity, it also
caused the swelling of the remaining vessels. By immunostaining for
α-SMA, we confirmed that most of these vessels were covered with
smooth muscle cells, thus explaining the moderate antiangiogenic
effect of RAPA on these CRLMs. The HRI results revealed dif-
ferences between the vasculature properties at the center of RAPA-
treated CRLM and the center of advanced CRLM lesions (≥7 mm).
These differences were further confirmed by histologic evaluation.
All of these findings emphasized the potency of HRI for understand-
ing the underling mechanism of antiangiogenic drugs with the goal
of developing strategies that could lead to earlier evaluation of the
therapeutic efficacy noninvasively.
The detection and characterization of primary hepatic nodules in
the multistage development of HCC in a cirrhotic liver remain an
important challenge for clinicians [30,31]. We assessed the potential
of HRI for HCC diagnosis based on the functional vascular profile of
a variety of hepatic lesions in the Mdr2 knockout mouse model [37].
By using HRI, we could distinguish three distinct patterns of re-
sponses to the inhaled gases, which were in good correlation to the
pathologic diagnosis. These results imply that HRI may facilitate the
differentiation between different types of hepatic lesions based on
their vascular profile noninvasively.
There are several limitations to the current study. First, liver fMRI
in humans can be limited by respiratory motion artifact, which may
reduce measurement accuracy and is very critical for achieving sig-
nificant ΔS maps. Respiratory motion artifacts can be suppressed
by navigator-gated methods [46] or corrected by postacquisition pro-
cessing [47]. Because our experiments were performed on anesthe-
tized mice, most of the motion artifacts were negligible, and there was
no need for additional data processing. Second, our HRI method is
Figure 6. Primary hepatic lesions vascular characterization by HRI:
Three distinct patterns of HRI responses were observed in hepatic
lesions identified in elderly Mdr2 knockout mice. (A) Representa-
tive T2W image of a 17-month-old Mdr2-knockout mouse on
which three different lesions are marked with white rectangles
(bar = 1 cm). (B–D) Each panel represents one pattern and contains
the corresponding enlarged T1W images obtained before and after
Gd injection (Top), and the corresponding enlarged HRI maps
(bottom, left—ΔSO2map; right—ΔSCO2map; color scale forΔSmaps
is shown on B). (B) Representative sample for pattern I—with hetero-
geneous HRI response that was found to be characteristic for poorly
differentiated HCC. (C) Representative example for pattern II—with
homogeneously elevated HRI response that was found to be distinc-
tive for well-differentiated HCC. (D) Representative sample of pattern
III—with reduced HRI response inside the lesion with high ΔS values
at the periphery that was found to be distinctive for necrotic foci.
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based on T2*-weighted images that are very sensitive to in-homogeneity
and could be very susceptible to intrasubject and intersubject variability.
To avoid this variability and to improveHRI reproducibility, we assessed
the potential usage of R2* maps during hyperoxia and hypercapnia chal-
lenges for CRLM detection in mice. Our preliminary results illustrate
that theHRI andΔR2*maps yield similar qualitative results (FigureW2),
suggesting that dynamic measurement may not be required, thus per-
mitting improved spatial resolution. Indeed, the use of R2* maps in
3-T clinical MR machine for liver fibrosis assessment with carbogen
challenge was recently demonstrated [48]. Finally, our experiments were
performed on animal models, and although the models resemble the
human disease, promising results ofHRI for liver tumor detection should
be further investigated and reproduced in patients with liver tumors.
In summary, HRI offers a new technique to monitor changes of
vessel density and perfusion ratio in liver tumors noninvasively with-
out the need for contrast agent administration. Our experimental data
from mice provide comprehensive evidence for the use of this method
for earlier and more accurate hepatic tumor diagnosis in both primary
andmetastatic tumors. In addition, this method can serve as an imaging
tool for the study of the underling mechanism of antiangiogenic drugs
based on the results regarding vascular alterations during RAPA treat-
ment. We believe that, by combining HRI with the well-established
perfusion imaging methods (CE-MRI, etc), hepatic tumor detection
and therapy monitoring could be improved.
Acknowledgments
The authors thank Evelyne Zeira for her helpful assistance with the
CRLM model establishment and Mery Clausen for article editing.
References
[1] El-Serag HB and Rudolph KL (2007). Hepatocellular carcinoma: epidemiology
and molecular carcinogenesis. Gastroenterology 132, 2557–2576.
[2] Llovet JM and Bruix J (2008). Novel advancements in the management of hepa-
tocellular carcinoma in 2008. J Hepatol 48(Suppl 1), S20–S37.
[3] Baker ME and Pelley R (1995). Hepatic metastases: basic principles and impli-
cations for radiologists. Radiology 197, 329–337.
[4] Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008).
Cancer statistics, 2008. CA Cancer J Clin 58, 71–96.
[5] McLoughlin JM, Jensen EH, and Malafa M (2006). Resection of colorectal liver
metastases: current perspectives. Cancer Control 13, 32–41.
[6] El-Serag HB, Marrero JA, Rudolph L, and Reddy KR (2008). Diagnosis and
treatment of hepatocellular carcinoma. Gastroenterology 134, 1752–1763.
[7] Finlay IG and McArdle CS (1983). Effect of occult hepatic metastases on survival
after curative resection for colorectal carcinoma. Gastroenterology 85, 596–599.
[8] Rothbarth J and van de Velde CJ (2005). Treatment of liver metastases of colo-
rectal cancer. Ann Oncol 16(Suppl 2), ii144–ii149.
[9] Ruers T and Bleichrodt RP (2002). Treatment of liver metastases, an update on
the possibilities and results. Eur J Cancer 38, 1023–1033.
[10] Vogl TJ, Zangos S, Eichler K, Yakoub D, and Nabil M (2007). Colorectal liver
metastases: regional chemotherapy via transarterial chemoembolization (TACE)
and hepatic chemoperfusion: an update. Eur Radiol 17, 1025–1034.
[11] Semela D, Piguet AC, Kolev M, Schmitter K, Hlushchuk R, Djonov V, Stoupis C,
and Dufour JF (2007). Vascular remodeling and antitumoral effects of mTOR
inhibition in a rat model of hepatocellular carcinoma. J Hepatol 46, 840–848.
[12] Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M,
Bruns CJ, Zuelke C, Farkas S, Anthuber M, et al. (2002). Rapamycin inhibits
primary and metastatic tumor growth by antiangiogenesis: involvement of vas-
cular endothelial growth factor. Nat Med 8, 128–135.
[13] Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, and Suthanthiran M
(2003). Rapamycin is an effective inhibitor of human renal cancer metastasis.
Kidney Int 63, 917–926.
[14] HojoM,Morimoto T,MaluccioM, Asano T,Morimoto K, LagmanM, Shimbo T,
and Suthanthiran M (1999). Cyclosporine induces cancer progression by a cell-
autonomous mechanism. Nature 397, 530–534.
[15] Luan FL, Hojo M, Maluccio M, Yamaji K, and Suthanthiran M (2002). Rapa-
mycin blocks tumor progression: unlinking immunosuppression from antitumor
efficacy. Transplantation 73, 1565–1572.
[16] Brindle K (2008). New approaches for imaging tumour responses to treatment.
Nat Rev Cancer 8, 94–107.
[17] Michaelis LC and Ratain MJ (2006). Measuring response in a post-RECIST
world: from black and white to shades of grey. Nat Rev Cancer 6, 409–414.
[18] Miller JC, Pien HH, Sahani D, Sorensen AG, and Thrall JH (2005). Imaging
angiogenesis: applications and potential for drug development. J Natl Cancer
Inst 97, 172–187.
[19] Checkley D, Tessier JJ, Kendrew J, Waterton JC, and Wedge SR (2003). Use of
dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a
VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 89, 1889–1895.
[20] Drevs J, Muller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H,
Konerding MA, Allegrini PR, Wood J, Hennig J, et al. (2002). PTK787/ZK
222584, a specific vascular endothelial growth factor-receptor tyrosine kinase
inhibitor, affects the anatomy of the tumor vascular bed and the functional vas-
cular properties as detected by dynamic enhanced magnetic resonance imaging.
Cancer Res 62, 4015–4022.
[21] Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir
P, Wheeler C, Stone A, Leadbetter J, et al. (2004). Magnetic resonance imaging
measurements of the response of murine and human tumors to the vascular-
targeting agent ZD6126. Clin Cancer Res 10, 3650–3657.
[22] Fuh G, Wu P, Liang WC, Ultsch M, Lee CV, Moffat B, and Wiesmann C (2006).
Structure-function studies of two synthetic anti–vascular endothelial growth factor
Fabs and comparison with the Avastin Fab. J Biol Chem 281, 6625–6631.
[23] Mross K, Drevs J, Muller M, Medinger M, Marme D, Hennig J, Morgan B,
Lebwohl D, Masson E, Ho YY, et al. (2005). Phase I clinical and pharmacoki-
netic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with
liver metastases from solid tumours. Eur J Cancer 41, 1291–1299.
[24] Barrett T, Brechbiel M, Bernardo M, and Choyke PL (2007). MRI of tumor
angiogenesis. J Magn Reson Imaging 26, 235–249.
[25] LeachMO,BrindleKM,EvelhochJL,Griffiths JR,HorsmanMR, JacksonA, Jayson
GC, Judson IR, Knopp MV, Maxwell RJ, et al. (2005). The assessment of anti-
angiogenic and antivascular therapies in early-stage clinical trials using magnetic res-
onance imaging: issues and recommendations. Br J Cancer 92, 1599–1610.
[26] Breedis C and Young G (1954). The blood supply of neoplasms in the liver. Am
J Pathol 30, 969–977.
[27] Pandharipande PV, Krinsky GA, Rusinek H, and Lee VS (2005). Perfusion im-
aging of the liver: current challenges and future goals. Radiology 234, 661–673.
[28] Leveson SH, Wiggins PA, Giles GR, Parkin A, and Robinson PJ (1985). De-
ranged liver blood flow patterns in the detection of liver metastases. Br J Surg
72, 128–130.
[29] Leen E, Goldberg JA, Angerson WJ, and McArdle CS (2000). Potential role of
Doppler perfusion index in selection of patients with colorectal cancer for ad-
juvant chemotherapy. Lancet 355, 34–37.
[30] Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK,
Christensen E, Pagliaro L, ColomboM, and Rodes J (2001). Clinical management
of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference.
European Association for the Study of the Liver. J Hepatol 35, 421–430.
[31] Bruix J and Sherman M (2005). Management of hepatocellular carcinoma.
Hepatology 42, 1208–1236.
[32] Coenegrachts K, Ghekiere J, Denolin V, Gabriele B, Herigault G, Haspeslagh M,
Daled P, Bipat S, Stoker J, and Rigauts H (2010). Perfusion maps of the whole
liver based on high temporal and spatial resolution contrast-enhanced MRI (4D
THRIVE): feasibility and initial results in focal liver lesions. Eur J Radiol 74,
529–535.
[33] Barash H, Gross E, Matot I, Edrei Y, Tsarfaty G, Spira G, Vlodavsky I, Galun E,
and Abramovitch R (2007). Functional MR imaging during hypercapnia and
hyperoxia: noninvasive tool for monitoring changes in liver perfusion and hemo-
dynamics in a rat model. Radiology 243, 727–735.
[34] Barash H, Gross E, Edrei Y, Pappo O, Spira G, Vlodavsky I, Galun E, Matot I,
and Abramovitch R (2008). Functional magnetic resonance imaging monitoring
of pathological changes in rodent livers during hyperoxia and hypercapnia. Hepa-
tology 48, 1232–1241.
[35] Matot I, Cohen K, PappoO, Barash H, and Abramovitch R (2008). Liver response
to hemorrhagic shock and subsequent resuscitation:MRI analysis. Shock29, 16–24.
[36] Kollmar O, Schilling MK, and Menger MD (2004). Experimental liver metas-
tasis: standards for local cell implantation to study isolated tumor growth in
mice. Clin Exp Metastasis 21, 453–460.
252 Liver Tumor Vasculature Assessment Using HRI Edrei et al. Neoplasia Vol. 13, No. 3, 2011
[37] Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH,
Notenboom RG, van den Bergh Weerman MA, Verkruisen RP, Groen AK,
Oude Elferink RP, et al. (1994). Mice with homozygous disruption of the mdr2
P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflam-
matory cholangitis and hepatocarcinogenesis. Am J Pathol 145, 1237–1245.
[38] Robinson PJ (2000). Imaging liver metastases: current limitations and future
prospects. Br J Radiol 73, 234–241.
[39] Blyth S, Blakeborough A, Peterson M, Cameron IC, and Majeed AW (2008).
Sensitivity of magnetic resonance imaging in the detection of colorectal liver
metastases. Ann R Coll Surg Engl 90, 25–28.
[40] Abramovitch R, Frenkiel D, and Neeman M (1998). Analysis of subcutaneous
angiogenesis by gradient echo magnetic resonance imaging. Magn Reson Med
39, 813–824.
[41] Leen E (1999). The detection of occult liver metastases of colorectal carcinoma.
J Hepatobiliary Pancreat Surg 6, 7–15.
[42] Liu Y and Matsui O (2007). Changes of intratumoral microvessels and blood
perfusion during establishment of hepatic metastases in mice. Radiology 243,
386–395.
[43] Dezso K, Bugyik E, Papp V, Laszlo V, Dome B, Tovari J, Timar J, Nagy P, and
Paku S (2009). Development of arterial blood supply in experimental liver metas-
tases. Am J Pathol 175, 835–843.
[44] ten Dam MA and Wetzels JF (2008). Toxicity of contrast media: an update.
Neth J Med 66, 416–422.
[45] FreimanM, Edrei Y, Sela Y, Shmidmayer Y, Gross E, Joskowicz L, and Abramovitch
R (2008). Classification of suspected liver metastases using fMRI images: a machine
learning approach. Med Image Comput Comput Assist Interv 11, 93–100.
[46] Song R, Cohen AR, and Song HK (2007). Improved transverse relaxation rate
measurement techniques for the assessment of hepatic and myocardial iron con-
tent. J Magn Reson Imaging 26, 208–214.
[47] White MJ, Hawkes DJ, Melbourne A, Collins DJ, Coolens C, Hawkins M,
Leach MO, and Atkinson D (2009). Motion artifact correction in free-breathing
abdominal MRI using overlapping partial samples to recover image deforma-
tions. Magn Reson Med 62, 440–449.
[48] Jin N, Deng J, Chadashvili T, Zhang Y, Guo Y, Zhang Z, Yang GY, Omary RA,
and Larson AC (2010). Carbogen gas-challenge BOLD MR imaging in a rat
model of diethylnitrosamine-induced liver fibrosis. Radiology 254, 129–137.
Neoplasia Vol. 13, No. 3, 2011 Liver Tumor Vasculature Assessment Using HRI Edrei et al. 253
Supplementary Methods
ΔR2* Maps
Multigradient echo (MGRE) was used to quantify the transverse re-
laxation rate R2*, with a repetition time of 200 milliseconds, an initial
echo time of 5 milliseconds, an echo time spacing of 5 milliseconds,
5 echo times, flip angleα = 40degrees, and 2 averages. The total imaging
time was approximately 3.5 minutes. Three sets of MGRE images were
acquired: 1) during breathing air, 2) after 3 minutes of 5%CO2 breath-
ing (4 L/min) through a mask, and 3) after a 3-minute carbogen breath-
ing (4 L/min).
Liver R2* (=1/T2*) maps for each slice were generated from the
MGRE images on a pixel-by-pixel basis by standard least square fit-
ting of the natural log of the signal intensity versus TE [1], for the
three inhaled gases. ΔR*CO2 was calculated by subtracting R2*-CO2
map from R2*-air map, and ΔR*O2 was calculated by subtracting
R2*-CO2 map from R2*-O2 map [2].
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Figure W1. HRI accuracy for suspected CRLM detection: (A) Axial T2W images (top) and HRI maps of ΔSO2 (center) and ΔSCO2 (bottom)
of a representative mouse with two suspected CRLM, acquired 14 days after cell injection (A, enlarged squares, ×3) and 4 days later (B).
Only one suspected focal lesion (red square) was classified as CRLM by HRI using a machine learning approach [3] (A) and was later
confirmed by standard MRI follow-up (B, red arrow and circles). Bar = 1 cm applies for all images. Color scale for ΔS maps are located
on the right.
Figure W2. HRI versus ΔR2*: Comparison between HRI maps and ΔR2* maps obtained from a CRLM-bearing mouse. (A) Axial T2W
image with five CRLM nodules (marked with red asterisks). (B) The corresponding ΔSO2 map (left) and ΔSCO2 map (right). (C) The
corresponding ΔR*O2 map (left) and ΔR*CO2 map (right). Bar = 1 cm in A and applies to all images. Color scale for ΔS and ΔR* maps
are located on the left (for hyperoxia) and right (for hypercapnia) [3].
